Navigation Links
Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
Date:4/27/2011

EAST BRUNSWICK, N.J., April 27, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the Bank of America Merrill Lynch 2011 Health Care Conference on Thursday, May 12, 2011, at 9:50 a.m. Pacific Time.  The conference will be held at Encore at the Wynn Las Vegas.

A live webcast of the presentation can be accessed through the investor relations section of the Savient website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.  Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA.  MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.  For more information, please visit the Company's website at www.savient.com.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
2. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
3. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
4. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
5. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
6. Savient Closes Sale of $230 Million in Convertible Senior Notes
7. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
8. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
9. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
10. Savient Pharmaceuticals Announces Search for CEO
11. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to the latest ... Market Study on Multiplex Detection Immunoassay: North America to ... global multiplex detection immunoassay market is expected to witness a CAGR ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
(Date:12/7/2016)... 2016 The global  blood ... of USD 3.9 billion by 2024, based on ... The growth of the market is attributed to ... advancements by the market players. Demand for blood ... donation, rising awareness about transfusion-transmitted diseases, and technological ...
(Date:12/6/2016)... 6, 2016  Alopexx Oncology, LLC announced data from ... fusion protein (immunocytokine) composed of interleukin-2 and a CD20-targeting ... on B cells as Rituxan and maintains the activities ... also involved in tumor targeting, engagement of the immune ... results of the study (abstract #95954) were presented at ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending ... the unique opportunity to get hands-on experience in an emergency medical simulation, When ... experience to gain invaluable, real-life medical skills that are critical success in a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... up with a schizophrenic mother in a unique, personal perspective through animation. ... treating trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to secure ... data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools ... need to operate in a GLP (Good Laboratory Practice) fashion. , With features designed ...
(Date:12/7/2016)... ... 2016 , ... Levels of a protein in the blood associated with heart ... in the journal Radiology. , Heart disease and brain disease exact a major burden ... aging population. Damage to both organs often occurs at a subclinical stage, or before ...
Breaking Medicine News(10 mins):